Graves ’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center

ConclusionGD-IA has an atypical course compared to classical forms of the disease. The identification of risk factors for the development of the disease before starting treatment with Alemtuzumab and early monitoring of thyroid function once this treatment is initiated prove to be useful strategies in the diagnosis and clinical management of this condition.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research